Spero Therapeutics: The Good News Already Happened, and the Stock Still Can't Get Off the Floor

# Spero Therapeutics: The Good News Already Happened, and the Stock Still Can't Get Off the Floor

Here's a fun exercise: name another biotech that reportedly landed a $105 million non-dilutive royalty deal with KKR, licensed an immunology asset to Innovent for up to $1.1 billion in milestones, and pushed its cash runway out toward the end of the decade — and got rewarded with a 52-week low. That's SPRO right now, sitting around $1.20-$1.27, RSI in the low 20s, trading roughly half its 200-day average. Somebody's buying that low, and it isn't anyone who read the press releases.

What we actually know

Spero has spent the last few months trying to reinvent itself. The old identity — antibiotics for multi-drug-resistant infections — was never a commercial darling; the antibiotics-market graveyard is full of well-designed drugs that couldn't clear reimbursement hurdles. The company's answer has been a pivot into immunology via a new program (SP001), and on the anti-infective side, the tebipenem HBr story finally reached its FDA moment.

That PDUFA date — June 18, 2026 — was the binary event everyone was waiting on for the oral carbapenem cUTI candidate, the one GSK already paid $25 million to license and is on the hook for over $300 million more in milestones if things go well. It's now nearly ten weeks in the rearview mirror. And here's the uncomfortable part of writing about this stock honestly: the public record around what actually happened on that date is murkier than it should be for a name that's supposedly cleared regulatory approval. What we do have is a Q2 report from August 12 that talks about a "strengthened balance sheet" and a runway pushed into 2029, plus separate signals pointing to a KKR royalty financing structure and an Innovent licensing deal — the kind of moves a company makes after it has something real (a brand name, a royalty stream, a marketable milestone asset) to monetize. Read between the lines and it looks like tebipenem cleared the bar. But "looks like" isn't "confirmed," and a stock at a 52-week low isn't screaming confidence either.

The numbers underneath the narrative

Q1 2026 wasn't pretty on its own terms: a $7.2 million net loss and revenue that reportedly collapsed 95% quarter-over-quarter to a mere $258,000 — a reminder that pre-approval, this is a company running on fumes and milestone checks, not a product business. Cash was $56.1 million as of Q1. Whatever happened between Q1 and Q2 — approval milestones, the KKR facility, the Innovent deal — apparently added enough juice to stretch that runway meaningfully further, which is the one unambiguously good thing here: less near-term dilution risk than the balance sheet alone would suggest.

Bull case vs. reality check

The bull case writes itself: first-in-class oral option in a real unmet-need indication, a deep-pocketed partner in GSK still owing north of $300 million in milestones, a newly diversified immunology pipeline with its own billion-dollar-plus optionality, and a runway that no longer forces a near-term equity raise. Slap analyst targets in the $4 range on that and you've got a "multiple your money" pitch.

The bear case is that none of this has stopped the chart from bleeding. Support at $1.40 and $2.00 is already broken. The stock is testing $1.20 with a path toward $1.08 if it can't hold. Oversold on RSI, sure — but oversold conditions in a stock that's down this much, this fast, aren't automatically a buy signal; they're often just the market telling you nobody wants to catch this yet. And even a tebipenem approval doesn't erase the historical graveyard of antibiotics that got FDA blessing and then died a slow commercial death from low prescriber uptake and stewardship-driven rationing. Approval is necessary. It has never been sufficient.

Where this leaves you

This is a name where the fundamental story — non-dilutive cash, extended runway, a diversified pipeline, real partner validation — has gotten repeatedly sold into rather than bought up, which tells you the market is discounting execution risk harder than it's crediting the catalysts. Until the stock can reclaim $1.27-$1.40 on volume, or until there's unambiguous, dated confirmation of exactly what the FDA decided and what the Innovent/KKR structures actually deliver, this stays a watch-and-wait, not a conviction buy. The next real gut-check is Q3 earnings, expected around November 12. Until then, the chart is the message, and the message is: prove it.